Tests elecoglipron against placebo in adults with chronic kidney disease
Tests elecoglipron versus placebo in adults with chronic kidney disease, alongside standard care.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Key facts
- Where
- Calgary, Edmonton, London, Montreal, Saint John, Scarborough Village, Sherbrooke, Toronto, Vancouver, Waterloo, and Winnipeg, CanadaSee the 11 sites
- Phase
- Phase 3
Where in Canada
- CalgaryCalgary, CanadaNot yet recruiting
- EdmontonEdmonton, CanadaNot yet recruiting
- LondonLondon, CanadaNot yet recruiting
- MontrealMontreal, CanadaNot yet recruiting
- Saint JohnSaint John, CanadaNot yet recruiting
- Scarborough VillageScarborough Village, CanadaNot yet recruiting
- SherbrookeSherbrooke, CanadaNot yet recruiting
- TorontoToronto, CanadaTaking people
- VancouverVancouver, CanadaNot yet recruiting
- WaterlooWaterloo, CanadaTaking people
- WinnipegWinnipeg, CanadaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07753993EU 2025-523994-41-00
- Record updated
- 9 September 2026
- Original description
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.Read full original descriptionShow less
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
Inclusion: Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges; On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.
Exclusion: Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness; Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening; History of type 1 diabetes mellitus; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; History/family history (first degree) of medullary thyroid cancer or MEN2; HbA1c ≥10% (86 mmol/mol) at screening; BMI <23 kg/m² at screening.